Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Standard Frontline Therapy for Endometrial Cancer

July 30th 2019

Updates in Testing Endometrial Cancer Biomarkers

July 30th 2019

Frontline Therapies for Metastatic Cervical Cancer

July 30th 2019

Cervical Cancer: Staging and Minimally Invasive Surgery

July 30th 2019

PARP Inhibitor Mechanisms of Resistance

July 30th 2019

PARP Inhibitor Toxicity Management

July 30th 2019

Maintenance Therapy: PARP Inhibitor or Bevacizumab

July 30th 2019

Managing Platinum-Resistance and Recurrent Disease

July 30th 2019

PARP Inhibitor Trial Updates

July 30th 2019

Treatment Options for Patients with BRCA1/2

July 30th 2019

Targeted Therapy Options for Advanced Ovarian Cancer

July 30th 2019

Systemic Therapy Selection for Advanced EOC

July 30th 2019

Promising PARP Inhibitor Strategies Emerging in Platinum-Sensitive Ovarian Cancer

July 24th 2019

Richard T. Penson, MD, MRCP, discusses novel strategies with PARP inhibitors and the use of biomarkers to create more personalized treatments for patients with platinum-sensitive ovarian cancer.

Evaluating Surgery and Angiogenesis Inhibition in Recurrent Ovarian Cancer

July 21st 2019

Angeles Alvarez Secord, MD, discusses the available treatment modalities for patients with platinum-sensitive and -resistant recurrent ovarian cancer.

Molecular Testing Continues to Evolve in Ovarian Cancer

July 19th 2019

Jubilee Brown, MD, discusses the importance of molecular testing immediately after an ovarian cancer diagnosis and how molecular testing will shape the field of ovarian cancer.

Quest Continues to Extend Reach of Immunotherapy, PARP Inhibitors in Ovarian Cancer

July 17th 2019

Matthew Powell, MD, discusses the trials that are generating excitement for combination immunotherapy as well as the impact of PARP inhibitors in the treatment of patients with ovarian cancer.

SOLO-1 Data Encourage Molecular Testing Immediately at Ovarian Cancer Diagnosis

July 17th 2019

Thomas Herzog, MD, discusses recent changes in the ovarian cancer landscape, specifically PARP inhibitors and the optimal use of bevacizumab.

Debate Continues Between Upfront Surgery and Neoadjuvant Chemo in Advanced Ovarian Cancer

July 16th 2019

R. Wendel Naumann, MD, discusses the criteria for primary debulking versus neoadjuvant chemotherapy in patients with advanced ovarian cancer.

Frontline Maintenance Niraparib Improves PFS in Ovarian Cancer

July 15th 2019

Niraparib as a maintenance treatment demonstrated a statistically significant improvement in progression-free survival compared with placebo in patients with ovarian cancer following first-line platinum-based chemotherapy, regardless of biomarker status, meeting the primary endpoint of the phase III PRIMA (ENGOT-OV26/GOG-3012) trial.

New Biomarkers for Responses Are Explored in Late-Stage Ovarian Cancer

July 4th 2019

The identification of appropriate biomarkers for evaluating responses to therapy would be beneficial across all stages of ovarian cancer, from early to advanced.